Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495920 · ClinicalTrials.gov registry record · Early Phase 1
Clinical Evaluation of the Residual Antimicrobial Activity
A Early Phase 1 study, sponsored by CAGE Bio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT04495920 is a Early Phase 1 study that has completed, run by CAGE Bio. The registered enrollment target is 12 participants.
The verdict
NCT04495920, a Early Phase 1 study, has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the residual antimicrobial efficacy of one test product as defined by the difference between the number of a challenge bacterial species recovered following exposure to the test product and the number recovered when untreated (negative control). The challenge bacterial species to be used is Staphylococcus aureus (ATCC #6538) (S. aureus). Testing will be carried out using a modification of the standardized test method described in ASTM E2752-10 (2015) Standard Guide for Evaluation of Residual Effectiveness of Antibacterial Personal Cleansing Products. Bacterial recoveries will be assayed after application oftest material, using the forearms as a substrate.
Interventions
- DRUG CGB-S-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2020-07-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495920
The ClinicalTrials.gov registry entry for NCT04495920 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CAGE Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CGB-S-100 is the first listed.
NCT04495920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04495920 about?
NCT04495920 is a clinical study titled "Clinical Evaluation of the Residual Antimicrobial Activity". The purpose of this study is to evaluate the residual antimicrobial efficacy of one test product as defined by the difference between the number of a challenge bacterial species recovered following exposure to the test product and the number recovered when untreated (negative control). The challenge...
What is the current status of trial NCT04495920?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2020-06-16. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT04495920?
The interventions under investigation include: CGB-S-100 (DRUG).
Who is sponsoring clinical trial NCT04495920?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.